Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.
Vincent H TamPaul R MerlauCole S HudsonEllen G KlineBrianna M EalesJames SmithAmelia K SofjanRyan K ShieldsPublished in: The Journal of antimicrobial chemotherapy (2022)
An optimal drug exposure to suppress KPC-producing bacteria was identified. The novel framework is informative and may be used to guide optimal dosing of other β-lactam/β-lactamase inhibitor combinations. Further in vivo investigations are warranted.